Goodwin Procter LLP and Dechert advised Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX) announced its acquisition of Minerva Neurosciences (Nasdaq: NERV) royalty interest in seltorexant…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now